Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Earlier we have showed that tumor
2022-07-12

Earlier we have showed that tumor associated sFas mRNA isoform profile and splicing factors expression levels in solid tumors do not correspond to profiles that are observed in cell lines [45]. In the present study, for the first time we show that Fas but not Rac1 pre-mRNA's alternative splicing is
-
Interestingly evidence has emerged recently
2022-07-12

Interestingly, evidence has emerged recently that suggests noncanonical roles of EZH2 in various cancers. For example, in addition to histone H3, EZH2 has been shown to methylate non-histone substrates, such as Jarid2 and STAT3, to regulate their transcriptional activities (He et al., 2012, Sanulli
-
Syt itself does not catalyze
2022-07-12

Syt1 itself does not catalyze lipid mixing and membrane fusion. Rather, the pairing of vesicular and target membrane SNAREs into complexes serves to pull bilayers together to drive fusion; Ca•syt1 accelerates these fusion reactions so that they occur on rapid timescales in a manner that is precisely
-
The ETA receptor has a higher affinity for endothelin
2022-07-12

The ETA receptor has a higher affinity for endothelin-1 than the two other agonists, with an affinity order of endothelin-1>endothelin-2>endothelin-3, while the ETB receptor exhibits similar affinities for all three isopeptides (Arai et al., 1990b, Sakurai et al., 1990). Earlier studies of the selec
-
Hyperhomocysteinemia HHcy is a clinical condition characteri
2022-07-12

Hyperhomocysteinemia (HHcy) is a clinical condition characterized by increased levels of plasma homocysteine (Hcy) and a well-known risk factor for CVDs. Hcy is a sulfur-containing non-protein amino nicotinic receptors formed during the intracellular conversion of methionine to cysteine. Previous s
-
br Multiple sclerosis MS is an
2022-07-12

Multiple sclerosis MS is an immune-mediated disease of the human CNS with a pathological signature featuring immunocyte infiltration, altered cytokine production, oligodendroglial degeneration, astrogliosis, microglial activation, multifocal demyelination and axonal degeneration (Schipper, 2004b)
-
Several bacterial functional pathways were observed after DO
2022-07-12

Several bacterial functional pathways were observed after DON administration, of which signal transduction, metabolism and genetic information processing displayed the highest levels of enrichment. Importantly, these three pathways were reported to be closely associated with DON's toxicity. Many evi
-
br Heme oxygenase inhibitors Historically
2022-07-12

Heme oxygenase-1 inhibitors Historically, the first class of competitive HO-1 inhibitors was represented by MPs, heme analogs in which the central iron Bikinin of heme is exchanged by another element, such as zinc, cobalt, tin, or chromium. These molecules compete with heme for binding to the en
-
In summary P P macrocyclization proved to be an effective
2022-07-12

In summary, P2-P4 macrocyclization proved to be an effective strategy to drive activity in this series of HCV NS3 protease inhibitors while microsomal stability was enhanced by the introduction of steric bulk along the tether. This modification augmented the previously-described tactic of improving
-
Substitutions V L F V and Q
2022-07-12

Substitutions V36L, F43V and Q80H were identified in the present study. RAS V36L is associated with resistance to boceprevir [18]. In 2015, Brazilian clinical practice guidelines on the management of hepatitis C no longer included combined therapies with boceprevir or telaprevir as a treatment optio
-
To identify structurally novel autophagy inhibitors a medium
2022-07-12

To identify structurally novel autophagy inhibitors, a medium throughput screen of our in-house library of approximately 160,000 compounds was performed. In the screening assay, MCF7 methysergide receptor stably transfected with eGFP-tagged light chain 3 (LC3), were employed, which can be detected
-
GSTP has an antiapoptotic activity
2022-07-12

GSTP1 has an antiapoptotic activity that is mediated by the inhibitory interaction with JNK1. Our data suggest that GSTP1 treatment is associated with a significant down-regulation of caspase expression. This might explain the reduction in infarct-related cardiomyocyte death and saving the cardiomyo
-
Furthermore the higher expression levels of DNMT seemed to b
2022-07-12

Furthermore, the higher expression levels of DNMT1 seemed to be responsible for the elevated levels of methylation in the GSTP1 and TXNRD2 promoters in HMC. In the DNA methyltransferase family, the functions of DNMT1 and DNMT3, including 3a and 3b, were the most ubiquitously expressed in cells. DNMT
-
Based on our finding that TFA modulates GlyR
2022-07-11

Based on our finding that TFA modulates GlyR function and reports that TFA-bound Colchicine can differ markedly from those synthesized without TFA, we retested a previously published dodecapeptide (D12-116) that also enhanced GlyR function but this time as a chloride salt (Tipps et al., 2010). No d
-
Acknowledgments br Introduction Type diabetes mellitus T
2022-07-11

Acknowledgments Introduction Type 2 diabetes mellitus (T2DM) is caused by relative insulin deficiency or insulin resistance in peripheral tissues. The clinical management of T2DM is achieved by controlling blood glucose levels. Current therapies available for treatment of T2DM include biguanides
11261 records 111/751 page Previous Next First page 上5页 111112113114115 下5页 Last page